Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CLOV stock price vs WST: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WST's multiple
Needs Annual EPS, WST P/E.
Implied fair value · at CLOV's multiple
Needs CLOV P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CLOVER HEALTH INVESTMENTS, CORP. /DE · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
WEST PHARMACEUTICAL SERVICES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Alignment Healthcare, Inc.
CLOV vs ALHC
Oscar Health, Inc.
CLOV vs OSCR
MOLINA HEALTHCARE, INC.
CLOV vs MOH
CENTENE CORP
CLOV vs CNC
APTARGROUP, INC.
CLOV vs ATR
BECTON DICKINSON & CO
CLOV vs BDX
ICU MEDICAL INC/DE
CLOV vs ICUI
TELEFLEX INC
CLOV vs TFX
BAXTER INTERNATIONAL INC
CLOV vs BAX
CARDINAL HEALTH INC
CLOV vs CAH
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CLOV can sustain 40.3% revenue growth while materially improving margins toward WST-like profitability, then the stock could merit a higher multiple because the current P/S of 1.0x is well below WST’s 7.3x; otherwise, the valuation gap looks justified by CLOV’s negative margins and negative ROIC.
Using WST P/S framework, CLOV’s current price of $3.92 sits far below the implied $27.62, implying 604.6% upside on a purely multiple-based basis. However, that gap is driven by WST’s much richer valuation profile and stronger earnings power, not by comparable operating quality.
Supporting Metrics
